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Abstract
Background: Antibiotic resistant strains of Acinetobacter baumannii have been responsible for an increasing
number of nosocomial infections including bacteremia and ventilator-associated pneumonia. In this study,
we analyzed 38 isolates of A. baumannii obtained from two hospital outbreaks in Los Angeles County for the
molecular epidemiology, antimicrobial susceptibility and resistance determinants.
Methods: Pulsed field gel electrophoresis, tri-locus multiplex PCR and multi-locus sequence typing (Pasteur scheme)
were used to examine clonal relationships of the outbreak isolates. Broth microdilution method was used to determine
antimicrobial susceptibility of these isolates. PCR and subsequent DNA sequencing were employed to characterize
antibiotic resistance genetic determinants.
Results: Trilocus multiplex PCR showed these isolates belong to Global Clones I and II, which were confirmed to ST1
and ST2, respectively, by multi-locus sequence typing. Pulsed field gel electrophoresis analysis identified two clonal
clusters, one with 20 isolates (Global Clone I) and the other with nine (Global Clone II), which dominated the two
outbreaks. Antimicrobial susceptibility testing using 14 antibiotics indicated that all isolates were resistant to antibiotics
belonging to four or more categories of antimicrobial agents. In particular, over three fourth of 38 isolates were found
to be resistant to both imipenem and meropenem. Additionally, all isolates were found to be resistant to piperacillin,
four cephalosporin antibiotics, ciprofloxacin and levofloxacin. Resistance phenotypes of these strains to
fluoroquinolones were correlated with point mutations in gyrA and parC genes that render reduced affinity
to target proteins. ISAba1 was detected immediately upstream of the blaOXA–23 gene present in those isolates
that were found to be resistant to both carbapenems. Class 1 integron-associated resistance gene cassettes
appear to contribute to resistance to aminoglycoside antibiotics.
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Conclusion: The two outbreaks were found to be dominated by two clonal clusters of A. baumannii
belonging to MLST ST1 and ST2. All isolates were resistant to antibiotics of at least four categories of
antimicrobial agents, and their antimicrobial susceptibility profiles correlate well with genetic determinants.
The results of this study will facilitate our understanding of the molecular epidemiology, antimicrobial
susceptibility and mechanisms of resistance of A. baumannii obtained from Los Angeles hospitals.
Keywords: Acinetobacter baumannii, Nosocomial outbreak, Epidemiology, Antimicrobial susceptibility,
Mechanism of resistance
Background
Acinetobacter baumannii, an emerging opportunistic
pathogen, is responsible for a significant proportion of
nosocomial infections including urinary tract infections,
endocarditis, surgical site infections, meningitis, septi-
cemia, and ventilator associated pneumonia among
intensive care unit patients in hospitals [1–5]. Add-
itionally, A. baumannii is recognized as an increasingly
important cause of community-acquired pneumonia
and other infections [6–11]. Currently, many nosoco-
mial clinical isolates of A. baumannii exhibit antimicro-
bial resistance towards most or all major classes of
antibiotics including β-lactams, aminoglycosides, fluor-
oquinolones (FQs), chloramphenicols, tetracyclines and
rifampin [12–16]. Four decades ago, these antibiotics
were effective in treating infections caused by this
bacterium. In particular, multidrug resistant clinical iso-
lates of this bacterium have been reported as infectious
agents in many soldiers wounded in Afghanistan and
Iraq [17–22].
A few years ago, we examined the phenotypic and mo-
lecular characteristics of 20 representative outbreak
isolates of A. baumannii obtained from Los Angeles
County (LAC) hospitals [14]. Subsequently, in vivo viru-
lence screens identified among these isolates a hypervir-
ulent strain (LAC-4) which was used to develop a mouse
model of A. baumannii-associated pneumonia [23].
Recently, we reported the complete genome of LAC-4
[24]. In this study, we determined antimicrobial suscep-
tibility and performed detailed molecular analyses of 38
additional isolates of A. baumannii derived from two
hospital outbreaks in Los Angeles County. Our report
provides critical insight into the development of anti-
microbial drug resistance, clonal dissemination and evo-
lution of clinical isolates of A. baumannii in LA County
hospitals.
Methods
Epidemiology and definitions of case and control
patients/isolates
A. baumannii isolates were collected as part of two sep-
arate healthcare-associated outbreak investigations that
occurred in two Los Angeles County hospitals in 2007
and 2009 respectively. Hospital A (Outbreak X) is a large
tertiary care teaching facility that provides general and
specialized medical services. The outbreak occurred in
the burn unit, a six-bed unit with two rooms located
across the hall from each other. Hospital B (Outbreak Y)
is a medium sized tertiary care facility that provides gen-
eral and specialized medical services. The outbreak oc-
curred in the medical intensive care unit. In both
outbreaks isolates from case patients (thus the isolates
are called case isolates) were cultured after the onset of
new symptoms, e.g. fever, increased sputum. Control pa-
tients had A. baumannii cultures during the outbreak
period from the same facility and, based on epidemio-
logic data, these cultures were determined to be unre-
lated to the outbreak (thus these isolates are called
control isolates). Control isolates were used as a baseline
for comparison of current strains circulating within the
facility. Environmental cultures were collected from
multiple unit surfaces of Hospital B, including patient
room sinks, faucets and door handles as well as ventila-
tor supplies and equipment. Environmental Cultures
were not collected from Hospital A. A. baumannii iso-
lates are shown in Table 1.
Additional bacterial strains
Quality control strains used in antimicrobial susceptibil-
ity testing [Escherichia coli (ATCC #25922) and Pseudo-
monas aeruginosa (ATCC #27853)] were purchased
from American Type Culture Collection (ATCC, Manas-
sas, VA). Additionally, A. baumannii strains AYE [12]
and CCF-9 [25] were used as positive controls for Global
Clones I and II (formerly known as International Clones
I and II), respectively. All strains were stored in 20 %
glycerol at – 80 °C.
Species-level confirmation of A. baumannii isolates
All isolates were previously determined to be A. bau-
mannii by hospital clinical laboratories. Species of these
isolates were further confirmed based on sequence ana-
lysis of 16S–23S rRNA gene intergenic spacer (ITS) re-
gions using modified methods [25] based on Chang and
coworkers [26].
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Pulsed field gel electrophoresis (PFGE)
Bacterial genomic DNA plugs were made from A. bau-
mannii isolates according to PulseNet USA standardized
laboratory protocol (http://www.cdc.gov/pulsenet/patho-
gens/index.html) for PFGE of E. coli O157:H7, Shigella,
and Salmonella with following modifications. Genomic
DNAs (in agarose plugs) released from lysed cells of all
isolates were digested with ApaI (40 U/μl) for 5 h at 30 °
C. Samples were run on 1 % SeaKem Gold pulsed field
agarose gels in 0.5 × TBE using a Bio-Rad CHEF-
Mapper XA Electrophoresis System in 0.5 × TBE for
18 h with an initial pulse at 5 s and final pulse at 13 s.
Table 1 A. baumannii isolates, nature of samples (case vs control), their collection dates, sites, source of outbreaks and PFGE type
Isolate No. Case/Control Collection Date Specimen Source Outbreak Code No. of Band Differences PFGE Type
LAC-201 Case 1 12/19/2007 BAL X 0 X–A
LAC–202 Case 1 12/14/2007 Blood X 0 X–A
LAC–203 Case 2 12/29/2007 Tip X 0 X–A
LAC–204 Case 2 12/30/2007 ETT X 0 X–A
LAC–205 Case 3 12/8/2007 Tip X 0 X–A
LAC–206 Case 3 11/29/2007 Tip X 0 X–A
LAC–207 Case 3 12/8/2007 BAL X 0 X–A
LAC–208 Case 4 11/20/2007 BAL X 0 X–A
LAC–209 Case 4 12/1/2007 Blood X 1 X–A1
LAC–210 Control 1 12/23/2007 Wound X 3 X–A2
LAC–211 Control 1 12/29/2007 Blood X 3 X–A2
LAC–212 Case 5 12/22/2007 BAL X 3 X–A3
LAC–213 Case 5 12/30/2007 BAL X 3 X–A3
LAC–214 Case 5 12/21/2007 ETT X 3 X–A3
LAC–215 Case 6 12/8/2007 Urine X 3 X–A3
LAC–216 Case 6 12/20/2007 Blood X 3 X–A3
LAC–217 Control 2 12/4/2007 Blood X 4 X–A4
LAC–218 Control 2 11/29/2007 Resp X 4 X–A4
LAC–219 Control 3 1/4/2008 Resp X 3 X–A5
LAC–220 Control 3 1/3/2008 Blood X 4 X–A6
LAC–221 Control 4 10/19/2007 BAL X >7 X–B
LAC–222 Control 4 11/10/2007 Blood X >7 X–B
LAC–223 Control 5 10/29/2007 BAL X >7 X–B1
LAC–224 Control 6 11/16/2007 Tip X >7 X–C
LAC–225 Control 6 11/22/2007 Resp X >7 X–C
LAC–226 Control 5 10/24/2007 Wound X >7 X–D
LAC–227 Case 1 8/4/2009 Sputum Y 0 Y–A
LAC–228 Case 2 8/24/2009 Sputum, Expectorated Y 0 Y–A
LAC–229 Case 3 8/31/2009 Sputum Y 0 Y–A
LAC–230 Case 4 9/3/2009 Sputum Y 0 Y–A
LAC–231 Environmental 9/15/2009 Environmental Y 0 Y–A
LAC–232 Environmental 9/15/2009 Environmental Y 0 Y–A
LAC–233 Environmental 9/15/2009 Environmental Y 0 Y–A
LAC–234 Case 5 8/6/2009 Sputum Y 1 Y–A1
LAC–235 Control 1 9/6/2009 Wound Y 1 Y–A2
LAC–236 Case 6 8/4/2009 Bronchoscopy Y >7 Y–B
LAC–237 Case 7 8/6/2009 Sputum Y >7 Y–B
LAC–238 Case 8 8/3/2009 Wound Y >7 Y–C
Abbreviations: BAL bronchoalveolar lavage, ETT endotracheal tube, resp respiratory, tip catheter tip
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To compare the results of each isolate on different gels,
Salmonella braenderup H9812 strain genomic DNA
digested with Xba I was used as DNA size standard. The
PFGE results were interpreted by categorizing gel lanes
visually, according to guidelines described by Tenover
and colleagues as used in our previous studies [14, 25,
27]. The genomic DNA banding patterns of the various
isolates generated by PFGE were analyzed for clonal
relationships using BioNumerics software, version 5.1
(Applied Maths, Austin, TX), using the UPGMA
(unweighted pair group method with arithmetic mean)
clustering method and the Dice similarity coefficient with
1.5 % band matching tolerance and 0.5 % optimization.
Tri-locus multiplex PCR
Tri-locus multiplex PCR was performed using genomic
DNA from these isolates to determine clonal relation-
ships (Global Clones I, II or III). Briefly, six pairs of PCR
primers designed by Turton and colleagues [28] were
used to perform two sets of multiplex PCR amplifica-
tions of ompA, csuE and blaOXA–51-like gene fragments
for each of the isolates using 5 Prime Taq polymerase
MasterMix (Gaithersburg, MD). PCR parameters con-
sisted of an initial denaturation at 94 °C for 3 min,
30 cycles of denaturation at 94 °C for 45 s, annealing
at 57 °C for 45 s, extension at 72 °C for 1 min, and a
final extension at 72 °C for 5 min. The isolates were
designated as A. baumannii Global Clones I, or II
based on criteria established for Group 2 and Group
1 strains, respectively [28].
Multi-locus sequence typing (MLST)
The MLST scheme described by Diancourt and co-
workers [29] was performed and the scheme defined
as Pasteur’s MLST scheme is now hosted at http://
pubmlst.org/abaumannii/ site of PubMLST database.
Briefly, the sequences of internal fragments of seven
house-keeping genes cpn60 (encoding 60-kDa chaper-
onin), fusA (protein elongation factor EF-G), gltA (the
citrate synthase), pyrG (CTP synthase), recA (homolo-
gous recombination factor), rplB (50S ribosomal pro-
teins L2) and rpoB (RNA polymerase subunit B) were
determined. PCR amplification was performed in sep-
arate reactions of a final volume of 50 μl containing
20 μl Taq polymerase MasterMix, 1 μl forward and r-
everse primers (10 μM) and 2 μl template DNA
(10 ng/μl). PCR amplification was carried out in the
GeneAmp 9700 system without a mineral oil overlay.
Thermocycler parameters included an initial melt at
94 °C for 2 min, followed by 35 cycles of 94 °C for
30 s, 50 °C for 30 s, 72 °C for 30 s, ending with a final
extension step of 72 °C for 5 min. After confirmation
of presence of robust amplicons at appropriate length, PCR
products were purified according to the manufacturer’s
instructions using a QIAquick PCR purification kit (Qiagen,
Valencia, CA) and then sequenced on an ABI 3730 auto-
mated fluorescent sequencer. Determination of the se-
quence type was carried out using the Pasteur MLST
Database on the http://pubmlst.org/abaumannii/ website.
Antimicrobial susceptibility testing
Antimicrobial susceptibility of the A. baumannii isolates
were determined using the broth microdilution proto-
cols of Clinical Laboratory Standards Institute [30]
against a total of 14 known antibiotics according to
methods described previously [14]. Cefotaxime, ceftazi-
dime, ceftriaxone, gentamicin, levofloxacin, ciprofloxa-
cin, piperacillin and polymyxin B were purchased from
Sigma-Aldrich (St. Louis, MO). Meropenem was from
US Pharmacopeia (Rockville, MD). Amikacin, cefepime,
gatifloxacin, imipenem and tobramycin were purchased
from Fisher Scientific (Tustin, CA).
Sequencing of QRDRs of gyrA and parC genes
The quinolone resistance determinant regions (QRDRs)
of A. baumannii genes gyrA and parC were sequenced
based on the methods described previously [14], with
the exception of a new forward PCR/sequencing primer
(5′-GTGTGCTTTATGCCATGCAC-3′) for the gyrA
QRDR. Sequence comparisons with the amino acid
sequences of wild type A. baumannii GyrA (acces-
sion No. X82165) and ParC (accession No. X95819)
QRDR regions [31, 32] were made to identify mu-
tated amino acids.
Detection of class 1 integrons
The presence or absence of Class 1 integrons in all 38
hospital isolates was determined by PCR using previ-
ously reported primers specific for the intI1 genes:
intI1L primer, 5′-ACATGTGATGGCGACGCACGA-3′;
intI1R primer, 5′-ATTTCTGTCCTGGCTGGCGA-3′
[33]. Amplification was performed using genomic DNA
as template as described previous for the QRDR of the
gyrA and parC genes [14], with the following parame-
ters: an initial template denaturation at 94 °C for 2 min;
36 cycles of 1 min denaturation at 95 °C, 30 s of anneal-
ing at 53 °C, and 2 min of extension at 72 °C; final ex-
tension at 72 °C for 10 min. Similarly, primers specific
to the 5′ and 3′conserved segments (CS) of class 1 inte-
grons (5′ CS primer, 5′-GGCATCCAAGCAGCAAG-3′;
3′ CS primer, 5′- AAGCAGACTTGACCTGA-3′) were
also chosen to amplify the variable regions, as previously
described by Levesque and coworkers [34]. After the
PCR products were confirmed by agarose gel electro-
phoresis analysis, successful amplicons were sequenced
as previously described for the QRDR of gyrA and parC
genes. DNA sequences were analyzed using NCBI
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BLAST program to identify the entities of the genes
within the variable regions.
Carbapenamase gene detection
The presence of four prevalent OXA carbapenemase
genes (blaOXA–23-like, blaOXA–24-like, blaOXA–51-like and
blaOXA–58-like) for all isolates was determined using
established procedures described by Woodford and col-
leagues [35]. Briefly, the multiplex PCR reactions using 4
pairs of published primers [35] were performed in the
GeneAmp 9700 system. The resulting agarose gel elec-
trophoresis revealed the presence or absence of a given
blaOXA allele based on the predicted amplicon sizes [35].
Detection of ISAba1
These hospital isolates were subsequently tested for the
presence of ISAba1 element, using procedures described
by Segal and coworkers [36]. Additionally, for those iso-
lates that were confirmed to harbor blaOXA–23, PCR
mapping experiments were performed to determine
whether there was an ISAba1 element upstream of the
blaOXA–23 gene using the ISAba1 forward primer and
the blaOXA–23-like gene reverse primer, 20 ng template
DNA, with the following PCR parameters: an initial de-
naturing step at 94 °C for 5 min, followed by 30 amplifi-
cation cycles of 94 °C for 25 s, 52 °C for 40 s and 72 °C
for 50 s, with a final extension step at 72 °C for 6 min.
Results and discussion
Epidemiology
All isolates were confirmed as belonging to A. bauman-
nii species based on sequence analysis of the 16S-23S
rRNA intergenic spacer (ITS) region (data not shown).
Outbreak X (n = 6 cases) and Outbreak Y (n = 8 cases)
were defined as hospital-acquired A. baumannii infec-
tions clustered in time and location. Thirty-five A. bau-
mannii clinical isolates, obtained from two large general
acute care hospitals (>300 beds) as part of two respective
outbreak investigations, were collected and analyzed
from twenty-one unique patients. Specimen sites in-
cluded respiratory (resp, sputum, endotracheal tube, and
bronchoalveolar lavage) (n = 19), blood (n = 7), catheter
tip (n = 4), wound (n = 4), and urine (n = 1) (Table 1).
Three additional isolates were collected from the hos-
pital environment in Outbreak Y (sink faucet, towel dis-
penser and ventilator tubing in the same room).
Outbreak X occurred in the burn intensive care unit. All
six cases (i.e., case patients) were admitted for severe
thermal injuries. Outbreak Y occurred in the critical care
unit of another hospital and involved cases who were
admitted for a variety of medical diagnoses including
respiratory failure, altered consciousness, dehydration,
abdominal distress, end stage renal disease, and stroke.
The remaining six patients in Outbreak X and the
remaining patient in Outbreak Y were considered con-
trols (i.e., control patients). The control patients in Out-
break X were admitted to intensive care units (n = 4) or
closed monitored units (n = 2), a step-down unit from
intensive care, for conditions that include wounds, can-
cer, trauma, sepsis, and necrosis. The control patient in
Outbreak Y was admitted to the telemetry unit for fever
and hypotension. For the twenty-one total patients, the
average age was 56 years (ranging from 19 to 85 years);
76 % (n = 16) were male and 24 % (n = 5) were female;
48 % of patients died (n = 10) with cause of death deter-
mined to be related to A. baumannii in three cases. The
average length of stay prior to date of first positive A.
baumannii culture was 25 days (range 1–109 days).
Pulsed field gel electrophoresis analysis
Pulsed field gel electrophoresis demonstrated relative re-
latedness of case isolates as compared to control isolates
in each outbreak respectively. In Outbreak X, eight iso-
lates from four cases (Cases 1–4) had indistinguishable
isolate patterns and were designated Type X-A (“X” was
added as a prefix to distinguish the PFGE types from
those of Outbreak Y), while one isolate from Case 4 was
designated Type X-A1 due to 1 band difference (Table 1
and Fig. 1 PFGE). The five isolates from the remaining
two cases (Case 5 and Case 6) were designated Type X-
A3, were indistinguishable from each other and had
three band differences from the major pattern of the
other cases (Table 1 and Fig. 1). Among the control iso-
lates, two isolates of Control 1 and one isolate of Con-
trol 3 showed three band differences from the major
pattern of the cases and were designated Type X-A2 and
Type X-A5, respectively. Two isolates of Control 2 and
the other isolate of Control 3 had four band differences
from the major pattern and were designated Type X-A4
and Type X-A6, respectively (Table 1 and Fig. 1 PFGE).
The isolates of the remaining three controls had greater
than seven band differences from the major pattern of
the cases, thus are considered not clonally related to
those described above and were designated Types X-B,
X-B1, X-C and X-D (Table 1 and Fig. 1). In Outbreak Y,
four cases (Cases 1–4) were indistinguishable and desig-
nated Type Y-A (Table 1 and Fig. 1). One case (Case 5)
and one control (Control 1) each had one band differ-
ence from the major pattern of the cases and were desig-
nated Types Y-A1 and Y-A2. All 3 patterns (Y-A, Y-A1,
and Y-A2) are between 1–3 band apart so they are con-
sidered closely related but are not the same, according
to Tenover et al [27]. Two cases (Case 6 and Case 7)
were indistinguishable from each other but had greater
than seven band differences from the other cases and
were designated Type Y-B, and the remaining case (Case
8) was greater than seven band different from the major
patterns of the cases and was designated Type Y-C
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(Table 1 and Fig. 1). The isolates with Types Y-B and Y-
C are deemed not clonally related to Types Y-A to Y-A2.
The three environmental isolates were also designated
Type Y-A, and had 0 band difference from the major
pattern of the cases (Table 1 and Fig. 1). Of note, in Out-
break X, one case (Case 4) and two controls (Control 3
and Control 5) had isolates collected from different sites
on different days that, though they were from the same
patient, differed from each other (Table 1). Among 38
isolates obtained from two hospital outbreaks, there
were two clonally related clusters: one cluster consisting
of isolates with Types X-A1 to X-A6 (n = 20) and the
other cluster of isolates with Types Y-A to Y-A2 (n = 9)
(Fig. 1). The remaining six isolates collected from Out-
break X were all from controls, while the remaining
three isolates from Outbreak Y were from three cases.
Typing of the isolates based on trilocus multiplex PCR
and MLST
To determine which Global Clone (previously known as
European Clone or International Clone) each of the A.
baumannii isolates belongs to, trilocus multiplex (TLM)
PCR was performed. Our results showed that, consistent
with PFGE profiles (Fig. 1), 20 isolates associated with
Outbreak X (14 case isolates, 6 control isolates) were
found to belong to Global Clone I and they are all
clonally related based on PFGE patterns (Fig. 1). In
contrast, all 12 isolates from Outbreak Y (including case,
control and environmental isolates) were found to belong
to Global Clone II and all but three (LAC-236. LAC-237
and LAC-238) were clonally related (Fig. 1). Interestingly,
six control isolates from three control patients in Out-
break X were also typed to Global Clone II (Fig. 1).
Fig. 1 The dendrogram of PFGE profiles of the 38 A. baumannii isolates and comparison of PFGE types, trilocus multiplex PCR types and MLST
sequence types. The dendrogram includes PFGE patterns of 38 isolates and the comparison was performed with the BioNumerics software v5.1
using the UPGMA (unweighted pair group method with arithmetic mean) clustering method and the Dice similarity coefficient with 1.5 % band
matching tolerance and 0.5 % optimization. The PFGE types were assigned, first based on the outbreaks (X or Y), then based to the degree of
similarity according to guidelines of Tenover and colleagues [27]
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To confirm TLM typing results, 13 representative A.
baumannii isolates from the outbreaks were examined
for their MLST sequence types (ST) based on the Pas-
teur Institute Scheme [29]. The MLST results with select
isolates showed those isolates typed to Global Clone I
were confirmed to be ST1 while those isolates typed to
Global Clone II were confirmed to be ST2 (Fig. 1).
These results confirmed that for these isolates, TLM
PCR assays accurately typed them to respective Global
Clones, consistent with their sequence typing. In sum-
mary, the first outbreak (X) involved the spread of 20
isolates assigned to PFGE types X-A to X-A6 which
belong to ST-1, the second outbreak (Y) resulted in the
spread of 9 isolates assigned to PFGE types Y-A to Y-A2
which belong to ST-2. Isolates with Y-B, Y-C patterns
are not related to Y-A, Y-A1 and Y-A2 isolates even
though they were also typed ST-2.
MLST, TLM and PFGE genotyping methods are fre-
quently used for epidemiological studies and the surveil-
lance of A. baumannii outbreaks [37, 38]. PFGE has
been considered the gold standard for outbreak investi-
gations due to its higher discriminatory power. For
years, PFGE had been the leading standard for typing of
A. baumannii isolates [38]. However issues related to
interlab exchange of data and reproducibility has raised
concerns about reliability and portability of the results.
While the TLM approach is simple to perform and has
higher throughput, it has failed to resolve strains belong-
ing to unusual lineages [24]. On the other hand, MLST
is highly discriminating and uses the DNA sequences of
several conserved housekeeping gene fragments [39]. It
has emerged as the preferred method to type A.
baumannii [40–42]. Our experience indicates that a
bipartite interrogation using both PFGE and MLST ap-
proaches is ideal in examination of molecular epidemi-
ology of A. baumannii isolates.
Antimicrobial susceptibility
To determine the antimicrobial susceptibility of these A.
baumannii isolates, minimal inhibitory concentrations
(MICs) were determined for a panel of 14 antibiotics
against the 38 isolates obtained from the two outbreaks
in Los Angeles County hospitals. Based on the MICs ob-
tained for each antibiotic for the two groups of isolates
(Outbreaks X and Y), MIC range, MIC50 and MIC90
values are summarized in Table 2. With the exception of
polymyxin B which is active against all isolates, MIC50
values of all antibiotics tested fell within resistant ranges
as defined by CLSI [43]. Specifically, all 38 isolates were
resistant to cefepime, cefotaxime, ceftazidime, ceftriax-
one, ciprofloxacin, levofloxacin and piperacillin (based
on MIC ranges, Table 2), some may even be called XDR
(extremely drug-resistant) (data not shown) as defined
by Magiorakos and colleagues [44]. Additionally, while
the X group of isolates (outbreak X) appeared to be
more heterogeneous than those of Y group (outbreak Y)
because of higher number of antibiotics with wide range
of MIC values, the MIC50 and MIC90 profiles were quite
similar between the two groups (Table 2).
There have been few reports on molecular epidemi-
ology and antimicrobial resistance of isolates of A.
baumannii obtained from hospitals in Los Angeles
metropolitan area. In one of such reports, we character-
ized genetic and antimicrobial resistance profiles of 20
representative outbreak isolates of A. baumannii derived
from hospitals in Los Angeles County, CA [14]. Using
PFGE technique, these 20 multidrug resistant A. bau-
mannii isolates were classified into eight epidemiologi-
cally distinct groups, which were consistent with
isolates’ antimicrobial susceptibility profiles [14]. Armed





Outbreak X (n = 26) Amikacin 1–256 256 256
Gentamicin 4–256 256 256
Tobramycin 0.5–256 256 256
Imipenem 2–32 16 32
Meropenem 8–64 32 64
Piperacillin 256 256 256
Cefepime 64–256 128 256
Cefotaxime 256 256 256
Ceftazidime 256 256 256
Ceftriaxone 256 256 256
Ciprofloxacin 64–256 256 256
Gatifloxacin 4–64 32 64
Levofloxacin 16–32 32 32
Polymyxin B 0.25–0.5 0.25 0.5
Outbreak Y (n = 12) Amikacin 256 256 256
Gentamicin 256 256 256
Tobramycin 256 256 256
Imipenem 1–32 32 32
Meropenem 2–32 32 32
Piperacillin 256 256 256
Cefepime 32 32 32
Cefotaxime 256 256 256
Ceftazidime 128–256 256 256
Ceftriaxone 256 256 256
Ciprofloxacin 64–128 128 128
Gatifloxacin 8–64 16 32
Levofloxacin 16–64 32 64
Polymyxin B 0.25 0.25 0.25
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with more sophisticated molecular typing methodolo-
gies, such as MLST, we recently typed nine of these
LAC isolates to ST10 (including LAC-4), five of them to
ST417, two of them to ST241, while four of them con-
firmed as ST2 [24]. Although all isolates from the
present study belong to ST1 and ST2 thus may not be
genetically related to those 20 isolates examined previ-
ously, the increase in resistance phenotypes of the 38
isolates is quite remarkable (Table 2), considering the
two batches of isolates were collected ten years apart.
For example, all of the case isolates in the present study
were resistant to all three aminoglycoside antibiotics
tested (data not shown), while 25 % of isolates (5/20)
from the previous batch were susceptible to amikacin
and tobramycin [14]. Secondly, with the exception of
three isolates (LAC-236, –237, and –238), all case
isolates from the present study were resistant to both
carbapenems (data not shown); in contrast, 50 % and
45 % of isolates from previous batch were susceptible to
imipenem and meropenem, respectively [14].
Recently, Miyasaki and coworkers examined in vitro
activity of antibiotic combinations against a panel of
multidrug resistant strains of A. baumannii collected
from Cedars-Sinai Medical Center in Los Angeles, CA
[45]. In their report, among 102 hospital-acquired MDR
A. baumannii isolates, 76 belonged to a major clone A
while eight to a minor clone B, as characterized by re-
petitive PCR amplification using the DiversiLab Acineto-
bacter Fingerprinting Kit [45]. Unfortunately, because
MLST tests were not performed by Miyasaki and col-
leagues, the genetic relationships of their isolates to
those described in our studies (Fig. 1) [14] are unknown.
In a study that reports immuno-protection against XDR
A. baumannii infection in mice, Luo and coworkers
described five isolates collected from in-patients at
Harbor-UCLA Medical Center, Los Angeles, CA, in
2009 [46]. These five isolates were found to exhibit re-
sistance phenotypes to at least one antimicrobial agents
of all but 2 categories of antimicrobial agents [46].
Mechanisms of resistance
Our antimicrobial susceptibility testing indicated that all
isolates were resistant to the three fluoroquinolone (FQ)
antibiotics, with the exception of one control isolate
which was intermediate to gatifloxacin (data not shown).
Point mutations in the QRDR of genes encoding the
GyrA and ParC subunits of DNA gyrase and DNA topo-
isomerase IV, respectively, are the primary mechanism
of high-level bacterial resistance to fluoroquinolones
(FQs) [31, 32]. These mutations and the resultant amino
acid changes led to an altered target protein structure
and reduced fluoroquinolones binding affinity [47]. To
confirm if this is the case for these A. baumannii iso-
lates, the QRDRs of the gyrA and parC genes of the 38
A. baumannii isolates were amplified via PCR and se-
quenced. Sequencing results indicated that with excep-
tions of control isolates LAC-222 and LAC-225, all the
remaining 36 isolates possess point mutations that led to
amino acid substitutions in both GyrA and ParC poly-
peptides (Table 3). In LAC-222, only one mutation that
occurred in gyrA gene was found, which explains the
intermediate phenotype of LAC-222 to gatifloxacin (data
not shown).
These results are consistent with the previous findings
that mutations in both GyrA and ParC are required for
high-level FQ resistance phenotypes [31]. Indeed, we
have previously reported that presence of mutations in
both gyrA and parC genes in A. baumannii isolates is
associated with high-level resistance to fluoroquinolones
[14, 25]. Similarly, other investigators have found
that possessing mutations in both gyrA and parC
genes is strongly correlated with high level resistance
to ciprofloxacin in A. baumannii isolates [18] or A.
pittii isolates [48].
To assess the role of Class 1 integrons and the associ-
ated antibiotic resistance gene cassettes in antibiotic re-
sistance phenotypes in the isolates, we performed PCR
screens against the 38 isolates for the presence of Class
1 integrons by amplifying the integrase gene. Our results
revealed that 31 of the 38 isolates harbored the integrase
gene (Table 3) and that the seven isolates without inte-
grase gene were all derived from control patients (Table 1
and Table 3). Subsequent conserved segment amplifica-
tion via PCR, followed by DNA sequencing, indicated
that all amplified conserved segments contain three anti-
biotic resistance genes sharing the same gene identity
and organization: aacA4, catB8 and aadA1 (Table 3).
Since aacA4 [aka aac (6’)-Ib] encodes aminoglycoside 6’-
N-acetyltransferase, which confers resistance to amikacin
and tobramycin, among others [49, 50], the presence of
this gene (Table 3) correlates well with the susceptibility
patterns of these 38 A. baumannii isolates because four
of the seven control isolates being negative for class 1
integron were found to be susceptible to at least two of
the three aminoglycoside antibiotics (data not shown).
The presence of the integrase gene in 31 of the 38 iso-
lates provides a critical surveillance parameter that is in-
dicative of acquisition of antibiotic resistance genes.
Integrons have been shown to be an important type of
mobile elements contributing significantly to the dissem-
ination of antibiotic resistance genes in Gram-negative
bacterial pathogens [51, 52]. It was interesting to note
that the majority of A. baumannii clinical isolates tested
in this study harbor Class 1 integron in their genomes
and the seven isolates without it were control isolates,
indicating that the control isolates had not yet acquired
the Class 1 integron. The fact that outbreak isolates
from two hospitals shared that same antibiotic resistance
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Table 3 GyrA and ParC amino acid substitutions and detection of Class 1 integrons in A. baumannii isolates
Isolate
No.
GyrA amino acid changes ParC amino acid changes Class 1 integron bla gene or ISAba1 PCR
Gly -81 Ser-83 TCA Ala-84 Glu-87 Ser-80 TCG Glu-84 integrase cassette organization OXA-23 OXA-24 OXA-51 OXA-58 ISAba1 IS/OXA-23 PCR
LAC–201 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–202 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–203 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–204 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–205 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–206 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–207 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–208 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–209 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–210 – Leu TTA – – Leu TTG – – + – + – + +
LAC–211 – Leu TTA – – Leu TTG – – + – + – + +
LAC–212 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–213 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–214 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–215 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–216 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–217 – Leu TTA – – Leu TTG – – + – + – + +
LAC–218 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–219 – Leu TTA – – Leu TTG – – + – + – + +
LAC–220 – Leu TTA – – Leu TTG – – + – + – + +
LAC–221 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
LAC–222 – Leu TTA – – – – + aacA4–catB8–aadA1 – – + – +
LAC–223 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
LAC–224 – Leu TTA – – Leu TTG – – – – + – +
LAC–225 – Leu TTA – – – – – – – + – +
LAC–226 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
LAC–227 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–228 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–229 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–230 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +














Table 3 GyrA and ParC amino acid substitutions and detection of Class 1 integrons in A. baumannii isolates (Continued)
LAC–232 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–233 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–234 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–235 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 + – + – + +
LAC–236 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
LAC–237 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
LAC–238 – Leu TTA – – Leu TTG – + aacA4–catB8–aadA1 – – + – +
Absence of mutations in gyrA or parC genes is denoted as “–“
Presence or absence of class 1 integrase gene is denoted as “+” or “–”














gene array suggests the prevalence of this particular type
of Class 1 integron in Los Angeles area. Such a gene
array, aacA4-catB8-aadA1, was also found in many
MDR A. baumannii clinical isolates collected from
prison inmates [25]. This same array of gene cassettes
has been identified in clinical isolates of A. baumannii
worldwide: in 25 of the 30 A. baumannii isolates in
Korea [53], in 47 of the 65 A. baumannii isolates in
Taiwan [54], in all 30 clonal isolates of carbapenem-
resistant A. baumannii involved in a hospital outbreak
in Latvia [55], and in 26 clinical isolates of A. baumannii
obtained in central Ohio, U.S.A. [56].
Carbapenem resistance in A. baumannii has been sug-
gested to contribute to increased risk of mortality in
patients infected with this bacterium [57]. In this study,
the majority of A. baumannii isolates tested were resist-
ant to both imipenem and meropenem, with a few iso-
lates exhibiting intermediate or susceptible phenotypes,
suggesting widespread resistant strain dissemination in
the LAC hospital setting. Multiplex PCR reactions using
primer pairs specific to four OXA carbapenemase genes
(blaOXA–23-like, blaOXA–24-like, blaOXA–51-like and blaOXA–
58-like) were performed against these 38 isolates. As
anticipated, blaOXA–51-like gene was detected in every A.
baumannii isolates (Table 3). Additionally, 29 out of 38
isolates (76 %) also harbor the blaOXA–23-like gene
(Table 3). Furthermore, none of the isolates harbors
blaOXA–24-like or blaOXA–58-like gene. Results from the
ISAba1 element PCR screens indicated that ISAba1 was
present in all of the 38 isolates (Table 3). Subsequent
PCR screens against the 29 blaOXA–23 positive strains
using ISAba1 forward and blaOXA–23 reverse primers
confirmed that all of these 29 isolates possess ISAba1
element upstream of the blaOXA–23 gene (Table 3), which
is consistent with the carbapenem resistant phenotypes
of these isolates. The remaining nine isolates without
the blaOXA–23 gene were either susceptible or intermedi-
ate to at least one carbapenem tested (data not shown).
Remarkably, 20 isolates of the clonal cluster (LAC-201
to –220) from Outbreak X and nine isolates of the clonal
cluster (LAC-227 to –235) from Outbreak Y all possess
ISAba1-linked blaOXA –23 gene (Fig. 1, Table 3) and they
all are resistant to both carbapenems (data not shown).
Carbapenems are considered the last resort to treat
infections caused by A. baumannii. In this study, we
showed that the majority of case isolates and some con-
trol isolates were resistant to both carbapenems, which
is of great concern. The carbapenem susceptibility phe-
notypes in these 38 A. baumannii isolates are clearly
correlated with the presence or absence, in the genomes
of the isolates, of ISAba1-linked blaOXA –23-LIKE genes.
Presumably, the ISAba1 element likely provides exogen-
ous promoter functions to over-express the linked genes,
as demonstrated previously [41, 58, 59]. In contrast,
among the 20 nosocomial outbreak isolates of A. bau-
mannii reported previously by us, 50 % and 45 % were
susceptible to imipenem and meropenem, respectively
[14], suggesting rapid dissemination of carbapenem re-
sistant genetic determinants over a ten-year span. In
fact, the LAC-4 strain, whose genome was completely
sequenced, and 19 other LAC isolates from the 2008 study
all lack blaOXA –23-like, blaOXA –24-like, and blaOXA –58-like
genes, even though ISAba1 was detected in all of these
isolates (data not shown). On the other hand, MDR A.
baumannii strains isolated recently were often found to
be resistant to carbapenems. For example, Hammerum
and coworkers described eight carbapenem-resistant A.
baumannii isolates in a Denmark hospital. These strains
were typed using Pasteur MLST Scheme to five ST2
isolates, two ST1 isolates and one ST158, all of which har-
boring either blaOXA –23 or blaOXA –72 (which is blaOXA –
24-LIKE) genes, consistent with carbapenem resistance
phenotype [40]. Additionally, 26 carbapenem-resistant A.
baumannii clinical isolates from two Italian hospitals were
characterized and typed to ST2 using MLST and all pos-
sess blaOXA –82 genes that are located downstream of
ISAba1 elements [60]. Finally, Teo and coworkers identi-
fied 49 MDR A. baumanniii clinical isolates that were re-
sistant to carbapenems and all isolates were found to
harbor both blaOXA –51 and blaOXA –23 genes, in accord-
ance with carbapenem resistant phenotypes [61].
Conclusions
This report presents the phenotypic and molecular ana-
lyses of 38 isolates of A. baumannii collected from two
hospital outbreaks in Los Angeles County. Based on
genetic patterns and molecular tests, one outbreak (Out-
break X) was dominated by a cluster of 20 clonally re-
lated isolates derived from Global Clone I or ST1
(MLST Pasteuar Scheme) while the other (Outbreak Y)
was dominated by a different cluster of nine clonally re-
lated strains belonging to Global Clone II or ST2. While
every single isolate (including environmental isolates
from the hospital) is multidrug resistant, all isolates were
found uniformly resistant to seven antibiotics belonging
to cephalosporin, penicillin and fluoroquinolone classes.
There was good correlation between antimicrobial sus-
ceptibility phenotypes and the presence of resistance
genetic determinants. In particular, it is alarming that
nearly all of these cluster isolates (except three that were
obtained from control patients) were resistant to both
imipenem and meropenem, which can be attributed to
presence of blaOXA –23 genes downstream of the ISAba1
in the genomes of these isolates. The results presented
here provide clinically relevant insights into antimicro-
bial susceptibility, clonal dissemination and mechanisms
of resistance in Los Angeles area hospitals.
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